Procter & Gamble Health Ltd
NSE: PGHL BSE: 500126
₹5210.50
(-1.78)%
Mon, 02 Feb 2026, 06:57 am
Market Cap87.98B
PE Ratio28.19
Dividend2.36
Health Technology
Pharmaceuticals: Major
24.5KAnalysis
dividend
- Dividends per share have increased over the past 10 years.
- Dividends paid are well covered by earnings (4.1x coverage).
- Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
- Procter & Gamble Health's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
- Procter & Gamble Health's dividend is below the markets top 25% of dividend payers in India (3.08%).
health
- Procter & Gamble Health is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Procter & Gamble Health is profitable, therefore cash runway is not a concern.
- Procter & Gamble Health is profitable, therefore cash runway is not a concern.
- Procter & Gamble Health has no debt, it does not need to be covered by operating cash flow.
- Procter & Gamble Health has no debt, it does not need to be covered by short term assets.
- Procter & Gamble Health's cash and other short term assets cover its long term commitments.
- Procter & Gamble Health has not taken on any debt in the past 5 years.
- Procter & Gamble Health has no debt, therefore coverage of interest payments is not a concern.
- Procter & Gamble Health has no debt.
- High level of physical assets or inventory.
management
- Milind's remuneration is lower than average for companies of similar size in India.
- The average tenure for the Procter & Gamble Health board of directors is less than 3 years, this suggests a new board.
misc
- Procter & Gamble Health is not covered by any analysts.
past
- Procter & Gamble Health's 1-year earnings growth exceeds its 5-year average (28.3% vs 25.7%)
- Procter & Gamble Health has delivered over 20% year on year earnings growth in the past 5 years.
- Procter & Gamble Health used its assets more efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Procter & Gamble Health has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
- Procter & Gamble Health has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
- Procter & Gamble Health's earnings growth has exceeded the IN Pharmaceuticals industry average in the past year (28.3% vs 22.7%).
value
- PGHL outperformed the Market in India which returned -14.5% over the past year.
- Procter & Gamble Health's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- Procter & Gamble Health's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
- Procter & Gamble Health is overvalued based on assets compared to the IN Pharmaceuticals industry average.
- Procter & Gamble Health is overvalued based on earnings compared to the IN Pharmaceuticals industry average.
- Procter & Gamble Health is overvalued based on earnings compared to the India market.
- PGHL underperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- NSEI:PGHL is down -1.1% underperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- NSEI:PGHL is down -1.1% underperforming the market in India which returned 8% over the past month.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800